Global Coagulation Albumin Market Size By Type (Liquid, Powder), By Application (Infectious Hepatitis, Measles), By Region, And Segment Forecasts, 2023 to 2032

The Global Coagulation Albumin Market was valued at USD 5.1 billion in 2023 and is projected to reach USD 8.4 billion by 2031, growing at a CAGR of 6.3% during the forecast period from 2023 to 2031. This market is experiencing strong growth due to increasing prevalence of liver diseases, rising surgical procedures requiring blood volume replacement, and the expanding use of albumin in therapeutic and diagnostic applications. The growing adoption of albumin as a plasma expander and its role in managing shock and burns are also significantly driving market demand.

Drivers

Rising Incidence of Liver and Kidney Disorders

With the global increase in chronic liver and kidney conditions, albumin is frequently used in patient treatment to restore blood volume and maintain osmotic pressure.

Growth in Surgical Procedures and Trauma Cases

Increasing surgical interventions, both elective and emergency, are fueling the demand for coagulation albumin to prevent hypovolemia and maintain plasma volume stability.

Expanding Application in Drug Formulation and Diagnostics

Albumin is widely utilized in drug delivery systems and diagnostic imaging, especially in oncology and infectious diseases, creating new growth avenues for the market.

Restraints

High Cost and Limited Supply

The extraction of albumin from human plasma is expensive and time-consuming, leading to limited availability and high prices that may restrict adoption in low-income regions.

Stringent Regulatory Framework

The production and usage of human plasma-derived products are subject to strict regulations concerning safety and quality, posing challenges for manufacturers.

Opportunity

Emergence of Recombinant Albumin

Biotechnological advances in recombinant albumin synthesis are opening new possibilities by overcoming supply limitations and offering pathogen-free alternatives.

Rising Healthcare Access in Emerging Economies

Developing countries are investing in expanding healthcare infrastructure, creating opportunities for broader access to albumin therapies.

Market by System Type Insights

Based on system type, the Human Serum Albumin segment held the largest share in 2023. This dominance is due to its widespread use in restoring blood volume, treating hypoalbuminemia, and in liver cirrhosis management. Meanwhile, the Recombinant Albumin segment is projected to grow rapidly owing to its scalability and lower risk of contamination.

Market by End-use Insights

In terms of end-use, Hospitals & Clinics emerged as the dominant segment, contributing over 60% to the global revenue in 2023. These settings are primary consumers of albumin for surgeries, trauma care, and intensive treatments. Research Institutes and Biotechnology Companies are also expanding their use, especially in drug development and cellular therapy.

Market by Regional Insights

Regionally, North America led the global coagulation albumin market in 2023, thanks to its advanced healthcare infrastructure, high prevalence of chronic conditions, and strong regulatory approval systems. Asia-Pacific is anticipated to register the fastest growth, propelled by expanding healthcare investments, growing medical tourism, and rising awareness about albumin-based treatments.

Competitive Scenario

Key players in the Global Coagulation Albumin Market include Grifols, S.A., CSL Limited, Octapharma AG, Kedrion S.p.A., Takeda Pharmaceutical Company Limited, Baxter International Inc., Biotest AG, and Merck KGaA. These companies are actively investing in R&D, strategic collaborations, and capacity expansion to strengthen their market position.

Scope of Work – Global Coagulation Albumin Market

Report Metric Details

Market Size (2023) USD 5.1 billion

Projected Market Size (2031) USD 8.4 billion

CAGR (2023–2031) 6.3%

Market Segments By System Type (Human Serum Albumin, Recombinant Albumin), End-use

Growth Drivers Rising liver disease incidence, increased surgeries, therapeutic use

Opportunities Recombinant albumin adoption, emerging healthcare markets

Key Market Developments

2023: CSL Limited launched a recombinant human albumin product aimed at expanding access in emerging markets.

2024: Grifols opened a new plasma collection center in the U.S. to address the growing demand for plasma-derived albumin.

2025: Octapharma AG received FDA approval for its latest albumin-based therapeutic used in pediatric critical care.

FAQs

What is the current market size of the Global Coagulation Albumin Market?

The market was valued at USD 5.1 billion in 2023.

What is the major growth driver of the Global Coagulation Albumin Market?

The major growth driver is the increasing prevalence of liver and kidney disorders requiring albumin-based treatment.

Which is the largest region during the forecast period in the Global Coagulation Albumin Market?

North America is the largest region due to advanced healthcare systems and high treatment adoption rates.

Which segment accounted for the largest market share in Global Coagulation Albumin Market?

The Human Serum Albumin segment accounted for the largest market share in 2023.

Who are the key market players in the Global Coagulation Albumin Market?

Key players include Grifols, CSL Limited, Octapharma AG, Kedrion, Takeda, and Baxter International.